Operating Income (Loss) of Co-Diagnostics, Inc. from 30 Jun 2016 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
Co-Diagnostics, Inc. quarterly and annual Operating Income (Loss) in USD history and change rate from 30 Jun 2016 to 30 Sep 2025.
  • Co-Diagnostics, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was $7,013,848, a 31% increase year-over-year.
  • Co-Diagnostics, Inc. Operating Income (Loss) for the twelve months ending 30 Sep 2025 was $35,530,592, a 11% increase year-over-year.
  • Co-Diagnostics, Inc. annual Operating Income (Loss) for 2024 was $40,081,310, a 6.1% increase from 2023.
  • Co-Diagnostics, Inc. annual Operating Income (Loss) for 2023 was $42,706,234, a 58% decline from 2022.
  • Co-Diagnostics, Inc. annual Operating Income (Loss) for 2022 was $26,979,837, a 159% decline from 2021.
Source SEC data
View on sec.gov
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Quarterly (USD)
Operating Income (Loss), YoY Quarterly Change (%)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Change (%)

Co-Diagnostics, Inc. Quarterly Operating Income (Loss) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $35,530,592 $7,013,848 +$3,221,089 +31% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $38,751,681 $8,057,764 -$377,802 -4.9% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $38,373,879 $8,551,956 +$1,707,431 +17% 01 Jan 2025 31 Mar 2025 10-Q 08 May 2025 2025 Q1
Q4 2024 $40,081,310 $11,907,024 -$81,830 -0.69% 01 Oct 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
Q3 2024 $39,999,480 $10,234,937 -$1,298,986 -15% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $38,700,494 $7,679,962 +$4,314,477 +36% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $43,014,971 $10,259,387 -$308,737 -3.1% 01 Jan 2024 31 Mar 2024 10-Q 08 May 2025 2025 Q1
Q4 2023 $42,706,234 $11,825,194 +$14,296,149 +55% 01 Oct 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
Q3 2023 $57,002,383 $8,935,951 -$2,400,336 -37% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $54,602,047 $11,994,439 -$7,847,401 -189% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $46,754,646 $9,950,650 -$19,774,809 -201% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $26,979,837 $26,121,343 -$36,430,108 -353% 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $9,450,271 $6,535,615 -$20,165,736 -148% 01 Jul 2022 30 Sep 2022 10-Q 09 Nov 2023 2023 Q3
Q2 2022 $29,616,007 $4,147,038 -$15,938,203 -135% 01 Apr 2022 30 Jun 2022 10-Q 10 Aug 2023 2023 Q2
Q1 2022 $45,554,210 $9,824,159 -$510,742 -4.9% 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q4 2021 $46,064,952 $10,308,765 -$5,720,345 -36% 01 Oct 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
Q3 2021 $51,785,297 $13,630,121 +$1,591,919 +13% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2022 2022 Q3
Q2 2021 $50,193,378 $11,791,165 -$2,917,112 -20% 01 Apr 2021 30 Jun 2021 10-Q 11 Aug 2022 2022 Q2
Q1 2021 $53,110,490 $10,334,901 +$11,416,850 01 Jan 2021 31 Mar 2021 10-Q 12 May 2022 2022 Q1
Q4 2020 $41,693,640 $16,029,110 +$17,652,508 01 Oct 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
Q3 2020 $24,041,132 $12,038,202 +$13,688,289 01 Jul 2020 30 Sep 2020 10-Q 12 Nov 2021 2021 Q3
Q2 2020 $10,352,843 $14,708,277 +$16,074,041 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2
Q1 2020 $5,721,198 $1,081,949 +$172,543 +14% 01 Jan 2020 31 Mar 2020 10-Q 13 May 2021 2021 Q1
Q4 2019 $5,893,741 $1,623,398 +$199,852 +11% 01 Oct 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
Q3 2019 $6,093,593 $1,650,087 +$13,682 +0.82% 01 Jul 2019 30 Sep 2019 10-Q 16 Nov 2020 2020 Q3
Q2 2019 $6,107,275 $1,365,764 -$12,398 -0.92% 01 Apr 2019 30 Jun 2019 10-Q/A 03 Nov 2020 2020 Q2
Q1 2019 $6,094,877 $1,254,492 +$22,939 +1.8% 01 Jan 2019 31 Mar 2019 10-Q 14 May 2020 2020 Q1
Q4 2018 $6,117,816 $1,823,250 -$329,560 -22% 01 Oct 2018 31 Dec 2018 10-K 30 Mar 2020 2019 FY
Q3 2018 $5,788,256 $1,663,769 +$141,291 +7.8% 01 Jul 2018 30 Sep 2018 10-Q 12 Nov 2019 2019 Q3
Q2 2018 $5,929,547 $1,353,366 -$652,414 -93% 01 Apr 2018 30 Jun 2018 10-Q 14 Aug 2019 2019 Q2
Q1 2018 $5,277,133 $1,277,431 -$713,066 -126% 01 Jan 2018 31 Mar 2018 10-Q 14 May 2019 2019 Q1
Q4 2017 $4,564,067 $1,493,690 01 Oct 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY
Q3 2017 $1,805,060 -$1,412,708 -360% 01 Jul 2017 30 Sep 2017 10-Q 14 Nov 2018 2018 Q3
Q2 2017 $700,952 -$310,661 -80% 01 Apr 2017 30 Jun 2017 10-Q 10 Aug 2018 2018 Q2
Q1 2017 $564,365 01 Jan 2017 31 Mar 2017 10-Q 14 May 2018 2018 Q1
Q3 2016 $392,352 01 Jul 2016 30 Sep 2016 10-Q 14 Nov 2017 2017 Q3
Q2 2016 $390,291 01 Apr 2016 30 Jun 2016 10-Q 25 Aug 2017 2017 Q2

Co-Diagnostics, Inc. Annual Operating Income (Loss) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $40,081,310 +$2,624,924 +6.1% 01 Jan 2024 31 Dec 2024 10-K 27 Mar 2025 2024 FY
2023 $42,706,234 -$15,726,397 -58% 01 Jan 2023 31 Dec 2023 10-K 27 Mar 2025 2024 FY
2022 $26,979,837 -$73,044,789 -159% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $46,064,952 +$4,371,312 +10% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $41,693,640 +$47,587,381 01 Jan 2020 31 Dec 2020 10-K 24 Mar 2022 2021 FY
2019 $5,893,741 +$224,075 +3.7% 01 Jan 2019 31 Dec 2019 10-K 25 Mar 2021 2020 FY
2018 $6,117,816 -$1,553,749 -34% 01 Jan 2018 31 Dec 2018 10-K 30 Mar 2020 2019 FY
2017 $4,564,067 -$2,876,101 -170% 01 Jan 2017 31 Dec 2017 10-K 01 Apr 2019 2018 FY
2016 $1,687,966 01 Jan 2016 31 Dec 2016 10-K 28 Mar 2018 2017 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.